Imperial College London

Professor Martin Wilkins

Faculty of MedicineDepartment of Medicine

Head of the Department of Medicine



+44 (0)20 3313 2049m.wilkins




NIHR / Wellcome Trust Clinical Research FacilityICTEM buildingHammersmith Campus






BibTex format

author = {Watson, G and Oliver, E and Zhao, L and Wilkins, MR},
doi = {10.1007/978-3-642-38664-0-21},
journal = {Handbook of Experimental Pharmacology},
pages = {531--548},
title = {Pulmonary hypertension: Old targets revisited (Statins, PPARs, Beta-Blockers)},
url = {},
volume = {218},
year = {2013}

RIS format (EndNote, RefMan)

AB - Pulmonary arterial hypertension is a therapeutic challenge. Despite progress in recent years with three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors-long-term patient survival remains poor. Importantly, the introduction and commercial success of these new treatments has been accompanied by growing interest in the pathology of pulmonary hypertension. This, in turn, has stimulated a re-evaluation of the molecular factors driving the structural remodelling of pulmonary arterioles and the opportunities to preserve right ventricular function in pulmonary hypertension. Academics with restricted access to new chemicals have turned to existing drugs to investigate new ideas. It is in this context that the role of statins, peroxisome proliferator-activated receptors (PPARs) and beta-blockers are of interest as potential treatments for pulmonary hypertension. © Springer-Verlag Berlin Heidelberg 2013.
AU - Watson,G
AU - Oliver,E
AU - Zhao,L
AU - Wilkins,MR
DO - 10.1007/978-3-642-38664-0-21
EP - 548
PY - 2013///
SN - 0171-2004
SP - 531
TI - Pulmonary hypertension: Old targets revisited (Statins, PPARs, Beta-Blockers)
T2 - Handbook of Experimental Pharmacology
UR -
VL - 218
ER -